Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Biological Therapy in Treating Patients With Primary or Advanced Glioma
This study has been suspended.
Sponsored by: Weill Medical College of Cornell University
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00003067
  Purpose

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or advanced glioma.

PURPOSE: Clinical trial to study the effectiveness of biological therapy with interleukin-2 and lymphokine-activated killer cells in treating patients who have primary, recurrent, or refractory malignant glioma.


Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug: aldesleukin
Drug: lymphokine-activated killer cells
Phase II

MedlinePlus related topics: Cancer
Drug Information available for: Aldesleukin Interleukin-2
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment
Official Title: Intracavitary Interleukin-2 (IL-2) and Lymphokine-Activated Killer (LAK) Cell Therapy for Malignant Gliomas

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: July 1997
Detailed Description:

OBJECTIVES:

  • Confirm the antitumor efficacy of intracavitary interleukin-2 plus autologous lymphokine-activated killer cells in patients with primary, recurrent or refractory malignant gliomas.
  • Determine whether the induction of a regional, intracavitary, eosinophilia is a prognosticator of response to immunotherapy and long term survival in these patients.

OUTLINE: Patients receive cytoreductive tumor surgery and/or biopsy and implantation of intracavitary Ommaya reservoir prior to therapy induction.

Patients undergo outpatient leukapheresis on day -4 or -5, and cells are incubated ex vivo with interleukin-2 (IL-2). Lymphokine-activated killer (LAK) cells and IL-2 are infused on day 1. Bolus infusions of low-dose IL-2 are administered on days 3, 5, 8, 10, and 12, followed by a rest period on days 13-24. The course is repeated on day 25 starting with leukapheresis. Therapy courses are repeated for up to 1 year for stable disease or response to therapy. Maintenance doses repeat every 4-6 months thereafter.

Disease restaging is done every 8-12 weeks.

PROJECTED ACCRUAL: A total of 30 patients per year will be enrolled.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or radiographically proven primary, recurrent, or refractory malignant gliomas (glioblastoma, anaplastic astrocytoma, and mixed anaplastic glioma)

    • Must be a candidate for neurosurgical biopsy or tumor debulking

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance Status:

  • Karnofsky 60-100%

Life Expectancy:

  • Greater than 4 months

Hematopoietic:

  • Granulocytes greater than 1,500/mm^3
  • Platelet count greater than 50,000/mm^3
  • PT and PTT within normal limits

Hepatic:

  • Bilirubin no greater than 1.5 times upper limit of normal

Renal:

  • Creatinine less than 1.5 mg/dL
  • Creatinine clearance greater than 60 mL/min

Cardiovascular:

  • No congestive heart failure
  • No coronary artery disease
  • No serious cardiac arrhythmias
  • No prior myocardial infarction

Pulmonary:

  • No major pulmonary problems

Other:

  • No history of neurologic disease (except related to brain tumor)
  • No psychosis
  • No impaired cognitive function
  • No significant concurrent medical illness
  • No active infection requiring antibiotic therapy
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Adequate peripheral veins to permit leukapheresis, or placement of indwelling central vascular access device
  • No hepatitis B or C
  • HIV negative
  • No prior autoimmune disease
  • Allergy to gentamicin is allowed

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 6 weeks since prior immunotherapy and recovered
  • No concurrent immunotherapy

Chemotherapy:

  • At least 4 weeks since prior chemotherapy (6 weeks for carmustine) and recovered
  • No concurrent chemotherapy

Endocrine therapy:

  • Reduction or elimination of corticosteroids
  • Not greater than 0.15 mg/kg/day dexamethasone equivalent

Radiotherapy:

  • At least 6 weeks since prior radiotherapy and recovered
  • No concurrent radiotherapy

Surgery:

  • Prior surgery is allowed

Other:

  • Concurrent therapy with acetaminophen, anticonvulsant agents, and headache pain medications is allowed
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003067

Locations
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10305
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Study Chair: Roberta L. Hayes, PhD Immune Therapy, LLC
  More Information

Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications of Results:
Study ID Numbers: CDR0000065739, NYWCCC-0902499, NYWCCC-IMMUNE-0902499, SIUH-RP-96-004, NCI-V97-1326
Study First Received: November 1, 1999
Last Updated: November 22, 2008
ClinicalTrials.gov Identifier: NCT00003067  
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent adult brain tumor
adult glioblastoma
adult anaplastic astrocytoma
adult mixed glioma
adult giant cell glioblastoma
adult gliosarcoma

Study placed in the following topic categories:
Glioblastoma
Astrocytoma
Central Nervous System Neoplasms
Recurrence
Brain Neoplasms
Neuroectodermal Tumors
Aldesleukin
Interleukin-2
Neoplasms, Germ Cell and Embryonal
Neuroepithelioma
Glioma
Gliosarcoma
Nervous System Neoplasms
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Anti-Infective Agents
Neoplasms by Histologic Type
Anti-HIV Agents
Antineoplastic Agents
Neoplasms, Nerve Tissue
Nervous System Diseases
Antiviral Agents
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Anti-Retroviral Agents
Therapeutic Uses
Neoplasms, Neuroepithelial

ClinicalTrials.gov processed this record on January 14, 2009